A Study of LY3127804 With Ramucirumab in Participants With Advanced Solid Tumors

I7W-MC-JQBA -

The main purpose of this study is to evaluate the safety of the study drug known as LY3127804 given as monotherapy and in combination with Ramucirumab for participants with advanced or metastatic solid tumors. The study will also include a safety exploration for the combination of LY3127804 plus ramucirumab and paclitaxel.

Trial Summary

Age Range
≥18 years
Conditions the trial is for
Solid Tumors
What the trial is testing?
Ramucirumab, LY3127804
Could I receive a Placebo?
No
Enrollment Goal
105
Trial Dates
Nov 6, 2015 - May 24, 2020
How long will I be in the trial?
Your participation could last up to 2 months depending on how you and your tumor respond.
Trial Phase
I

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participant must have a diagnosis of cancer that is advanced and/or metastatic

  • Participant must have adequate organ function

Participants Must Not:

  • Participant must not have any current blood cancers

  • Participant must not have an active fungal, bacterial, and/or known viral infection

  • Participant must not have a history or dangerously high blood pressure, headache, convulsions, or coma related to high blood pressure or poorly controlled hypertension despite standard medical management

  • Participant must not be pregnant or breastfeeding

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.